Small Cell Lung Cancer

The FDA has granted orphan drug designation to serplulimab for the treatment of patients with small cell lung cancer.

Eric Nadler, MD, MPP, discusses the design and goals of a retrospective study of real-world adoption of atezolizumab immunotherapy in extensive-stage small cell lung cancer.

In an interview with Targeted Oncology, Ravi Salgia, MD, PhD, discussed the research leading to the first-in-human study of LB-100 combined with chemotherapy or immunotherapy to address transformation to small cell lung cancer.

Afshin Dowlati, MD, discusses treatment decision-making for patients with late-stage small cell lung cancer.

Treatment locations in New York, New Jersey, and Florida are recruiting patients with mall cell lung cancer to receive olaparib and low-dose radiotherapy in a phase 1 clinical trial.

Joshua K. Sabari, MD, discusses the trials that showed efficacy for durvalumab and atezolizumab in patients with extensive-stage small cell lung cancer.

During a live virtual event, Melissa L. Johnson, MD, discussed how to treat a 73-year-old patient who was recently diagnosed with extensive-stage small cell lung cancer.

The immunotherapy combination of nivolumab and ipilimumab did not extend progression-free survival in patients with small cell lung cancer when compared with placebo.

Leora Horn, MD, discusses the importance of the Impower133 trial.

In the second interview of the series, Dr. Lowell L. Hart of Florida Cancer Specialists & Research Institute considers the impact of chemotherapy-induced myelosuppression in small cell lung cancer and examines how trilaciclib fits into the current treatment landscape.

In the phase 3 IMforte clinical trial, researchers are exploring lurbinectedin and atezolizumab as induction and maintenance therapy for patients with extensive-stage small cell lung cancer.

In 2019, there were approximately 30,000 new cases of small cell lung cancer diagnosed in the United States with nearly all cases attributable to cigarette smoking.

Small cell lung cancer is the most aggressive form of lung cancer and mostly occurs in smokers. Although the disease has proved to be sensitive to chemotherapy and radiation, responses are short and those who relapse have short survival.

In a 73-year-old patient, a PET scan revealed activity in the left upper lobe mass, supraclavicular nodal areas, and liver lesions, and an MRI discovered 1 small asymptomatic brain lesion. This lead to a diagnosis of stage T3N3M1-IV extensive-stage small cell lung cancer.

During a Targeted Oncology™ Cased-Based Roundtable event, Meghan Mooradian, MD, discussed the case of a 73-year-old patient with extensive stage-small cell lung cancer.

In patients with extensive-stage small cell lung cancer, durvalumab added to platinum/etoposide chemotherapy continued to demonstrate an overall survival improvement compared with chemotherapy alone with a favorable safety profile, according to updated data from the phase 3 CASPIAN trial.

"We are pleased to bring a new treatment choice to relapsed SCLC patients."